BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31263891)

  • 1. Prevention of chronic diseases in middle-age women: a cross-sectional study on an Italian large sample.
    Colombo A; Voglino G; Sessa A; Bert F; Maestroni AM; Lo Moro G; Caielli R; Siliquini R; Della Rosa MC
    Eur J Public Health; 2020 Feb; 30(1):70-75. PubMed ID: 31263891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
    Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
    Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
    Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
    Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
    Martinón-Torres F; Halperin SA; Nolan T; Tapiéro B; Perrett KP; de la Cueva IS; García-Sicilia J; Stranak Z; Vanderkooi OG; Kosina P; Rumlarova S; Virta M; Arribas JMM; Miranda-Valdivieso M; Novas BA; Bozensky J; Ortega MJC; Amador JTR; Baca M; Palomino EE; Zuccotti GV; Janota J; Marchisio PG; Kostanyan L; Meyer N; Ceregido MA; Cheuvart B; Kuriyakose SO; Mesaros N
    Vaccine; 2021 Mar; 39(11):1598-1608. PubMed ID: 33612341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
    Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
    J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
    John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
    Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
    Sricharoenchai S; Sirivichayakul C; Chokephaibulkit K; Pitisuttithum P; Dhitavat J; Pitisuthitham A; Phongsamart W; Boonnak K; Lapphra K; Sabmee Y; Wittawatmongkol O; Chinwangso P; Poredi IK; Petre J; Thai PH; Viviani S
    Lancet Infect Dis; 2018 Jan; 18(1):58-67. PubMed ID: 29066131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of antibodies specific to diphtheria toxoid, tetanus toxoid, and Haemophilus influenzae type b in healthy children born to Tdap-vaccinated mothers.
    Wanlapakorn N; Maertens K; Thongmee T; Srimuan D; Thatsanathorn T; Van Damme P; Leuridan E; Poovorawan Y
    Vaccine; 2020 Oct; 38(44):6914-6921. PubMed ID: 32888740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
    Kretsinger K; Broder KR; Cortese MM; Joyce MP; Ortega-Sanchez I; Lee GM; Tiwari T; Cohn AC; Slade BA; Iskander JK; Mijalski CM; Brown KH; Murphy TV; ; ;
    MMWR Recomm Rep; 2006 Dec; 55(RR-17):1-37. PubMed ID: 17167397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.
    Pool V; Tomovici A; Johnson DR; Greenberg DP; Decker MD
    Vaccine; 2018 Apr; 36(17):2282-2287. PubMed ID: 29573876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
    Weston W; Messier M; Friedland LR; Wu X; Howe B
    Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial.
    Wanlapakorn N; Maertens K; Vongpunsawad S; Puenpa J; Tran TMP; Hens N; Van Damme P; Thiriard A; Raze D; Locht C; Poovorawan Y; Leuridan E
    Clin Infect Dis; 2020 Jun; 71(1):72-80. PubMed ID: 31418814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of tetanus-diphtheria- acellular pertussis vaccination among adults receiving tetanus vaccine in the United States: data from the 2008 national health interview survey.
    Johns TL; Roetzheim R; Chen R
    J Prim Care Community Health; 2013 Apr; 4(2):95-100. PubMed ID: 23799715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
    Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
    Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
    Embree J; Law B; Voloshen T; Tomovici A
    Clin Vaccine Immunol; 2015 Mar; 22(3):282-90. PubMed ID: 25540274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.